Education
About Us
Working with TipRanks
Follow Us
ARKG - ETF AI Analysis
Top Page
ARK Genomic Revolution ETF (ARKG)
Rating:52Neutral
Price Target:
$27.00
Positive Factors
Strong Year-to-Date Performance
The ETF has shown solid gains this year, reflecting positive momentum in its holdings.
Focus on Health Care Innovation
With over 90% exposure to the health care sector, the fund targets cutting-edge genomic and biotech companies with growth potential.
Top Holdings Driving Growth
Several key positions, like Tempus AI and Adaptive Biotechnologies, have delivered strong year-to-date performance, supporting the fund’s returns.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee compared to many other funds, which can eat into long-term returns.
Over-Concentration in Health Care
With nearly all assets in the health care sector, the fund is vulnerable to industry-specific risks.
Limited Geographic Diversification
The ETF is heavily concentrated in U.S. companies, offering little exposure to international markets.
ARKG Historical Chart
AUM1.07B
RegionGlobal
Expense Ratio0.75%
Beta1.65
IssuerARK
Inception DateOct 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,024,684
30 Day Avg. Volume3,422,549
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
39.27Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering36
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ARKG Summary
The ARK Genomic Revolution ETF (ARKG) is an investment fund focused on companies driving advancements in genomics, biotechnology, and healthcare innovation. It includes businesses working on cutting-edge technologies like gene editing and DNA sequencing. Some of its top holdings are Crispr Therapeutics and Intellia Therapeutics, which are leaders in genetic research. Investors might consider ARKG for its potential high growth opportunities in the rapidly evolving field of genomics. However, it’s important to note that this ETF is heavily concentrated in healthcare and biotech, meaning its performance can be volatile and tied to the success of these industries.
How much will it cost me?The ARK Genomic Revolution ETF (ARKG) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, allowing it to focus on innovative companies in the fast-evolving genomics sector.
What would affect this ETF?The ARK Genomic Revolution ETF (ARKG) could benefit from continued advancements in genomic technologies like CRISPR and bioinformatics, as well as increased global investment in healthcare innovation. However, it may face challenges from regulatory hurdles in biotechnology, potential economic downturns affecting funding for research, and competition within the healthcare sector. Its global exposure and focus on cutting-edge companies provide growth potential, but also come with risks tied to market volatility and the success of its top holdings.
ARKG Top 10 Holdings
The ARK Genomic Revolution ETF (ARKG) is heavily concentrated in healthcare and biotechnology, with a global focus on cutting-edge genomic advancements. Guardant Health and Natera are rising stars in the portfolio, benefiting from strong revenue growth and bullish momentum, while Illumina shows steady recovery despite some financial hurdles. On the flip side, Crispr Therapeutics and Twist Bioscience are lagging, weighed down by profitability challenges and bearish trends. With its focus on transformative innovation, the fund’s performance hinges on balancing high-growth opportunities with the financial risks of its niche sector.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Tempus AI, Inc. Class A | 9.50% | $107.85M | $12.51B | 19.95% | 49 Neutral | |
| Crispr Therapeutics AG | 7.95% | $90.22M | $4.79B | 4.91% | 40 Underperform | |
| Personalis | 6.34% | $71.96M | $864.07M | 180.40% | 50 Neutral | |
| Guardant Health | 6.07% | $68.96M | $13.64B | 222.88% | 58 Neutral | |
| Twist Bioscience | 5.23% | $59.36M | $1.75B | -32.37% | 47 Neutral | |
| 10x Genomics | 4.97% | $56.43M | $2.32B | 28.16% | 60 Neutral | |
| Natera | 4.73% | $53.65M | $31.83B | 37.89% | 68 Neutral | |
| Illumina | 4.15% | $47.14M | $18.92B | -11.62% | 73 Outperform | |
| Beam Therapeutics | 4.11% | $46.64M | $2.25B | -11.34% | 40 Neutral | |
| Adaptive Biotechnologies | 4.07% | $46.22M | $2.84B | 296.80% | 54 Neutral |
ARKG Technical Analysis
Positive
―
Price Trends
29.20
Negative
27.03
Positive
24.97
Positive
Market Momentum
-0.62
Positive
51.94
Neutral
55.12
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARKG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.78, equal to the 50-day MA of 29.20, and equal to the 200-day MA of 24.97, indicating a neutral trend. The MACD of -0.62 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 55.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARKG.
ARKG Peer Comparison
Comparison Results
Performance Comparison
ARKG
ARK Genomic Revolution ETF
29.02
4.18
16.83%
BAI
iShares A.I. Innovation and Tech Active ETF
―
―
―
ARKK
Ark Innovation Etf
―
―
―
ARKW
ARK Next Generation Internet ETF
―
―
―
ARKQ
ARK Autonomous Technology & Robotics ETF
―
―
―
FWD
AB Disruptors ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents